Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting

RIDGEFIELD, Conn., Oct. 1, 2013 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

Presentations will include data from several studies evaluating Boehringer Ingelheim's investigational compound, faldaprevir, including final results from the STARTVerso1, 2 and 3 pivotal trial programs (NCT01343888, NCT01297270, NCT01358864) in treatment-naive and treatment-experienced patients. End-of-treatment results from STARTVerso 4 (NCT01399619) evaluating HIV/HCV co-infected patients will also be presented.

Additionally, data will be presented from studies evaluating drug-drug interactions of faldaprevir with common birth control and anti-addiction medications, as well as a study evaluating faldaprevir pharmacokinetics, safety, and tolerability in patients with renal impairment. Final results from SOUND-C3 (NCT01132313), a Phase 2b study from Boehringer Ingelheim's interferon-free development program, will also be presented.

Together these studies explore the use of Boehringer Ingelheim's investigational HCV compounds in a broad range of patients with HCV, in addition to helping understand the potential for interactions with several commonly used medications. Also, they offer insight into the clinical profile of the compounds for researchers and healthcare professionals looking for potential new treatment options for patients with HCV.

"We are pleased to see the presentation of the final results from STARTVerso1, 2 and 3, Boehringer Ingelheim's pivotal Phase 3 program in our hepatitis C portfolio, as well as other important analyses evaluating various patient subgroups at this year's AASLD meeting," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These data, combined with that of our interferon-free trial, SOUND-C3, are evidence of our commitment to researching new therapeutic options for patients infected with HCV."

Faldaprevir and deleobuvir are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Boehringer Ingelheim's abstracts can be accessed on the AASLD website today at www.aasld.org.

Poster Presentations

Title

Lead Author

Presentation Details

Effect of multiple oral doses of

faldaprevir on the multiple dose

pharmacokinetics of a combination

oral tablet of ethinylestradiol and

levonorgestrel in healthy

premenopausal female volunteers

J. Sabo

ID# 482

Session: HCV Therapy: The
Developmental Pipeline

Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall

Mass balance, metabolic profile

and the role of hepatic and

bacterial enzymes in the

metabolism of the HCV

polymerase inhibitor, deleobuvir

(BI 207127)

R. Sane

ID# 491

Session: HCV Therapy: The
Developmental Pipeline

Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall

Pharmacokinetics, safety, and

tolerability of faldaprevir in patients

with different levels of renal impairment

F. Huang

ID# 466

Session: HCV Therapy: The
Developmental Pipeline

Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall

Effect of steady-state faldaprevir

on the pharmacokinetics of steady-state

methadone and buprenorphine/naloxone

in subjects on stable addiction

management therapy

D. Joseph

ID# 483

Session: HCV Therapy: The
Developmental Pipeline

Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall

A pooled analysis of two randomized,

double-blind placebo-controlled

Phase III trials (STARTVerso1&2) of

faldaprevir plus pegylated interferon

alfa-2a and ribavirin in treatment-naive

patients with chronic hepatitis C

genotype-1 infection

D. Jensen

ID# 1088

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

Subgroup analyses and baseline

predictors of response with faldaprevir

plus pegylated interferon alfa-2a

and ribavirin in treatment-naive patients

with chronic hepatitis C genotype-1

infection: a pooled analysis of

STARTVerso1 and 2

E.M. Yoshida

ID# 1114

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

STARTVerso3: A randomized,

double-blind, placebo-controlled

Phase III trial of faldaprevir in

combination with pegylated interferon

alfa-2a and ribavirin in

treatment-experienced patients with

chronic hepatitis C genotype-1 infection

I. Jacobson

ID# 1100

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

Interferon-Free Treatment with

Faldaprevir, Deleobuvir (BI 207127)

and Ribavirin in SOUND-C3: 95% SVR12

in HCV-GT1b

J.F. Dufour

ID# 1102

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

STARTVerso 4 Phase III trial of

faldaprevir plus peg interferon alfa-2a

and ribavirin (PR) in patients with HIV

and HCV genotype 1 coinfection:

end of treatment response

J. Rockstroh

ID# 1099

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

Pharmacokinetic interactions of

Faldaprevir and Deleobuvir (BI 207127)

and their individual and combined effect on

selected cytochrome P450 (CYP) probe

substrates in genotype 1 hepatitis C

infected patients

C. Cooper

ID# 1083

Session: HCV Therapeutics: New
Agents

Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso is a multi-study Phase 3 trial program that evaluates faldaprevir combined with PegIFN/RBV. The four trials that make up this program study the combination in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis C is a blood-born infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000-12,000 deaths in the United States per year.

About Boehringer Ingelheim 
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information please visit www.us.boehringer-ingelheim.com.

Contact:
Boehringer Ingelheim Pharmaceuticals, Inc.

Name: Susanne Granold
Public Relations
Phone: 203-791-5851
Email: Susanne.Granold@boehringer-ingelheim.com

SOURCE Boehringer Ingelheim



RELATED LINKS
http://www.us.boehringer-ingelheim.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.